Dare Bioscience, Inc. Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand how Dare Bioscience performed this year. Instead of digging through dense legal filings, we’ll break down the company’s progress, their financial health, and what you should watch as an investor.

1. What does this company do and how did they perform?

Dare Bioscience is a clinical-stage biopharmaceutical company focused on women’s health. They act as an "innovation lab," finding late-stage medical products and partnering with larger companies to bring them to market.

In 2025, Dare shifted its business model to address cash shortages by adopting a "dual-path" approach. They are now selling compounded drugs—custom-made medications—through Section 503B outsourcing facilities. This allows them to generate immediate revenue without the multi-year, multi-million dollar FDA approval process, while they continue pursuing traditional approvals for their core pipeline.

2. Major wins and new products

The company is transitioning from a research entity to a commercial business:

• DARE to PLAY™: Launched in December 2025, this topical cream treats female sexual arousal disorder. By using the 503B pathway, Dare bypassed the traditional FDA timeline to start direct-to-physician sales.
• DARE to RESTORE™: The company expects to launch Flora Sync LF5™, a vaginal probiotic, in the second quarter of 2026. This targets the consumer wellness market.
• XACIATO®: This remains their flagship FDA-approved product for bacterial vaginosis. It is sold by Organon, which pays Dare a portion of sales. In 2024, XACIATO generated about $1.3 million for Dare.

3. Financial health: The "Cash-Burn" reality

Dare spends more than it makes, reporting a loss of about $35.4 million for 2024. To keep running, they rely on:

• Royalty Deals: In 2023, Dare traded future royalties from XACIATO to XOMA Royalty Corporation for $20 million upfront.
• Capital Raises: The company frequently sells new stock to the public. In 2024, this provided necessary cash but created more shares, which reduces your ownership percentage in the company.
• The Goal: The company aims to reach a "self-sustaining" level where 503B product sales cover the high costs of developing their hormone therapy programs.

4. Key risks

Investors should watch these critical risks:

• Dilution: The company relies heavily on selling new stock. With about 100 million shares outstanding, continued stock sales will likely keep downward pressure on the share price.
• Regulatory Risks: The 503B strategy is risky. These drugs are not FDA-approved. If the FDA restricts the ingredients used by Dare’s partners, the company must stop selling those products immediately.
• Dependency: Dare lacks its own sales force. Their revenue depends entirely on Organon’s marketing and the reliability of third-party manufacturers.
• Going Concern: Auditors warned that Dare’s $5.5 million in cash (as of late 2024) is not enough to fund operations for the next 12 months without raising more money.

5. Future outlook

Dare is trying to build a self-sustaining business. By using the 503B pathway to generate early revenue, they hope to build a cash cushion. The goal is for product sales to cover their operating costs, allowing them to advance their clinical pipeline without constantly issuing new shares.

Note: This guide is for informational purposes and is not financial advice. Before investing, consider whether the company's transition to a commercial model can generate enough cash to offset their high research costs and avoid further dilution of your shares.